MARKET OUTLOOK Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (UC), whereas tumor necrosis factor-alpha (TNF-α)…
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Opioid-induced constipation (OIC) is the most common side effect of opioid therapy because of the distribution of opioid receptors throughout the GI tract. Although OTC treatment for OIC is common…
In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (Janssen) have been leading the U.S. psoriasis biologics market. However, the recent…
Primary biliary cholangitis (PBC) is a disease characterized by autoimmune destruction of small bile ducts, thereby preventing bile mobilization and increasing hepatic bile content. These symptoms…
This folder covers DRG’s Company & Drugs (C&D) data for Transplants which include market forecast (US, ROW and Global) and analysis on drug profie, drug group and therapy area.
Gout is a chronic condition characterized by intermittent acute flares caused by elevated serum uric acid (sUA). Treatment of the painful acute flares is distinct from the chronic management of…
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irreversible loss of lung function, leading to high…
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and…
Like other retinal disease therapy markets, the retinal vein occlusion (RVO) with macular edema (ME) market in the United States is unique in that it is dominated by Genentech’s Avastin, an…
DRG Epidemiology's coverage of acute myeloid leukemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
The number of incident cases of AML in the countries under study will increase by 43%, from 58,000 to 82,000, in ten years. Of the countries considered in this analysis, the incidence of AML is…
The number of incident cases of AML in the Asia-Pacific countries under study will increase by 36%, from 10,500 to 14,200, in ten years. Of the countries considered in this analysis, the…
The number of incident cases of AML in the countries under study will increase by 33%, from 3,866 to 5,116, in ten years. Of the countries considered in this analysis, the incidence of AML is…
The number of incident cases of AML in the countries under study will increase by 38%, from 3,150 to 4,300, in ten years. Of the countries considered in this analysis, the incidence of AML is…